Precigen (PGEN) Total Current Liabilities (2012 - 2026)
Precigen (PGEN) reported Total Current Liabilities of $21.1 million for Q1 2026, down 12.02% year-over-year from $24.0 million in Q1 2025, and down 43.43% quarter-over-quarter from $37.3 million in Q4 2025.
Precigen (PGEN) Total Current Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Total Current Liabilities data on file, last reported at $21.1 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $21.1 million, down 12.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.1 million (down 12.02% YoY), and the FY2025 annual result was $37.3 million, up 73.37% from the prior year.
- Total Current Liabilities slipped to $21.1 million in Q1 2026 per PGEN's latest filing, from $37.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $104.9 million in Q3 2022 and troughed at $21.1 million in Q1 2026.
- A 5-year average of $35.6 million and a median of $28.8 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 261.74% in 2022, then tumbled 70.77% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $78.6 million in 2022, then plunged by 70.77% to $23.0 million in 2023, then retreated by 6.38% to $21.5 million in 2024, then jumped by 73.37% to $37.3 million in 2025, then slumped by 43.43% to $21.1 million in 2026.
- Business Quant data shows PGEN's Total Current Liabilities at $21.1 million in Q1 2026, $37.3 million in Q4 2025, and $32.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 72.86 Mn |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | 21.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.10 Mn |
| Dec 31, 2025 | 37.31 Mn |
| Sep 30, 2025 | 32.07 Mn |
| Jun 30, 2025 | 23.19 Mn |
| Mar 31, 2025 | 23.99 Mn |
| Dec 31, 2024 | 21.52 Mn |
| Sep 30, 2024 | 21.22 Mn |
| Jun 30, 2024 | 23.02 Mn |
| Mar 31, 2024 | 28.77 Mn |
| Dec 31, 2023 | 22.99 Mn |
| Sep 30, 2023 | 32.88 Mn |
| Jun 30, 2023 | 30.77 Mn |
| Mar 31, 2023 | 46.73 Mn |
| Dec 31, 2022 | 78.65 Mn |
| Sep 30, 2022 | 104.86 Mn |
| Jun 30, 2022 | 29.90 Mn |
| Mar 31, 2022 | 25.60 Mn |
| Dec 31, 2021 | 34.65 Mn |
| Sep 30, 2021 | 28.99 Mn |
| Jun 30, 2021 | 28.87 Mn |